An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Clinical trial NCT05884255 · RECRUITING

Trial details

NCT number: NCT05884255
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Start date: 2023-07-06
Primary completion: 2026-12-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.